Aprogen Terminates Exclusive License Agreement with Parmesin for Immune Anticancer Drug, Receives Refund of Down Payment and Penalty

Aprogen decided to terminate the exclusive technology license agreement for an immune anticancer drug entered into with Parmesin Inc. in August 2025.
The counterparty refunded the down payment and agreed penalty, and the board approved the termination after confirmation.
While Aprogen loses exclusive rights to the technology, no financial loss was incurred due to the refund.
[AI Summary]This termination may disrupt Aprogen's immune anticancer drug pipeline, but the returned funds can be redeployed. Short-term stock price impact is negative but limited given the absence of financial loss.